Our Turnover Has Grown 65 Per Cent In Comparison To 2015-16 And Looking To Grow 40 Per Cent This Year

IIL is a leading manufacturer of human and animal vaccines in India and other global markets. Dr K Anand Kumar, MD, Indian Immunologicals Ltd (IIL) divulges details about his company's growth plans for the future, its current R&D pipeline, trends in vaccine development, IIL's role in India Immunisation Programme and more, in an interaction with Lakshmipriya Nair

Can you give us an overview of the competitive landscape in the vaccines market, in India and globally? What is IIL’s market share of the total pie?

The total size of the human domestic trade market in India is about $333 million and is dominated by multinational companies such as GSK, Sanofi and Pfizer. The domination is on account of vaccines which are not supplied by Indian companies such as pneumococcal vaccine, HPV, Varicella etc. The top three brands in the trade market are Synflorix (pneumococcal vaccine by GSK), Hexaxim (hexavalent vaccine by Sanofi) and Prevenar 13 (pneumococcal vaccine by Pfizer). The three together command 22 per cent of the market size. The higher sales figure is on account of the higher price of the vaccine sold by the MNCs and not based on the units consumed.

The situation is different in India where an Indian company makes a vaccine. IIL is the leader in anti-rabies vaccine segment, Biological Evans is the leader in TT, Bharat Biotech is the leader in Typhoid Conjugate vaccine. IIL holds 36 per cent of the market share in the anti-rabies vaccine segment. Several Indian companies have a growing list of vaccines in their R&D pipeline and in the years to come the present dominance of the MNCs will be dented for sure.

In addition to the human domestic trade market, the government procures vaccines worth $250 million.

Total veterinary vaccine market in India, which includes the domestic trade market and government business, is $133 million. 60 per cent of that is for the poultry segment. IIL holds 53 per cent of the market share in the served market and 23 per cent in the overall market.

In the days to come, what will be the major drivers which will define the vaccine market in both, veterinary biologicals and human vaccines?